Related Experiment Video
Updated: Aug 8, 2026

Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation
Published on: March 5, 2018
Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent
Andrew M Evens1, Sheila Prachand, Bo Shi
1Departments of Medicine and Pathology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA.
Insights
Imexon demonstrates broad antimyeloma activity by inducing apoptosis, independent of reactive oxygen species (ROS) production. This cytotoxicity mechanism is caspase-8 dependent in both sensitive and resistant myeloma cells.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Imexon, a 2-cyanoaziridine agent, previously showed efficacy against chemotherapy-sensitive myeloma cells.
- Its mechanism involved apoptosis, reduced glutathione, and increased reactive oxygen species (ROS).
Purpose of the Study:
- To investigate the mechanism of imexon cytotoxicity in various myeloma cell lines.
- To assess imexon's efficacy against dexamethasone- and chemotherapy-resistant myeloma cells.
Main Methods:
- Cytotoxicity, apoptosis, and redox state were examined in sensitive and resistant myeloma cell lines.
- Caspase-3 and caspase-8 activity, Bcl-2:bax ratio, glutathione levels, and ROS production were analyzed.
Main Results:
- Imexon exhibited time- and dose-dependent cytotoxicity across all tested myeloma cell lines.
- Apoptosis, marked by cleaved caspase-3, was the primary mechanism of imexon-induced cell death.
- Caspase-8-dependent apoptosis was observed in specific cell lines.
- Glutathione depletion and ROS generation occurred only at high imexon concentrations in certain cell lines, without significant DNA damage.
Conclusions:
- Imexon possesses broad antimyeloma activity mediated by apoptosis.
- The cytotoxic effect is not dependent on ROS production.
- A caspase-8-dependent mechanism contributes to imexon's cytotoxicity in dexamethasone-sensitive and -resistant myeloma cells.
Purpose:
Imexon is a 2-cyanoaziridine agent that has been shown to inhibit growth of chemotherapy-sensitive myeloma cells through apoptosis with decreased cellular stores of glutathione and increased reactive oxygen species (ROS). We examined the mechanism of imexon cytotoxicity in a diverse panel of dexamethasone and chemotherapy-sensitive and -resistant myeloma cell lines.
Experimental Design:
We examined cellular cytotoxicity, apoptosis, and changes in redox state in dexamethasone-sensitive (C2E3), dexamethasone-resistant (1-310 and 1-414), chemotherapy-sensitive (RPMI-8226), and chemotherapy-resistant (DOX-1V and DOX-10V) myeloma cell lines.
Results:
We found significant cytotoxicity after 48-h incubation with imexon (80-160 microM) in dexamethasone and chemotherapy-sensitive and -resistant myeloma cell lines in a time- and dose-dependent manner. The mechanism of imexon cytotoxicity in all cell lines was related to induction of apoptosis with the presence of cleaved caspase-3. Moreover, after imexon exposure in C2E3 and 1-414 cell lines, we demonstrated caspase-8-dependent apoptosis. Bcl-2:bax was proapoptotic with imexon in C2E3, whereas bcl-2:bax was independent of steroid resistance, chemotherapy sensitivity, and chemotherapy resistance. Depletion of intracellular glutathione was documented in RPMI-8226 at high imexon concentrations (>or=225 microM) but not in other cell lines. Furthermore, ROS were found in C2E3, RPMI-8226, and 1-310 only at high imexon concentrations, whereas a sensitive marker of oxidative DNA damage, 8-hydroxydeoxyguanosine, was not increased in any cell line.
Conclusions:
Our results demonstrate that imexon has significant broad antimyeloma activity that is mediated through apoptotic mechanisms that is not dependent on production of ROS. Moreover, we have identified a mechanism of cytotoxicity in dexamethasone-sensitive and -resistant myeloma cells induced by imexon that is caspase-8 dependent.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Apoptosis
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy

